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We investigated the influence of high sucrose diet (HSD) 
after 3 or 5 weeks of administration on paraoxonase 1 
(PON1) activity in plasma of normolipidemic rats and 
the relationship between serum PON1 activity, triacylg-
lycerides (TGs), HDL and total cholesterol vs. the control 
group of rats fed normal, control diet (CD). Because the 
data about the influence of gemfibrozil (GEM) on PON1 
activity are controversial, we also investigated its effects 
(administration in the 4th and 5th week in rats on HSD 
and CD) on plasma PON1 activity and lipid levels in nor-
molipidemic rats, and in rats with hypertriglyceridemia 
caused by HSD. Our results obtained in rats on HSD 
show a significant increase of plasma TGs levels by 47  % 
(P < 0.05) after 5 weeks of treatment, and PON1 activ-
ity by 32  % and 23  % (P < 0.05) after 3 and 5 weeks, but 
without change in lipid levels vs. rats on CD. In the rats 
on CD and HSD, GEM caused a significant decrease of 
PON1 activity by 44  % and 33  %, while a significant de-
crease of TGs level by 38 % (P < 0.05) was measured only 
in rats on CD. The effects of GEM on total cholesterol, 
HDL and LDL in both groups of rats were typical for its 
action on lipoprotein metabolism. Because GEM in the 
rat liver stimulates proliferation of peroxisomes, β oxida-
tion, and production of H2O2, it is possible that the oxi-
dative stress induced by GEM damages hepatocytes and 
lowers the synthesis of PON1.
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INTRODUCTION
Plasma paraoxonase 1 (PON1) (aryldialkylphosphatase, 
EC 3.1.8.1) is an esterase, synthesized by the liver and 
secreted into the plasma, where it is associated with high-
density lipoproteins (HDL) and apolipoprotein AI (apo 
AI), the structural peptide of HDL. PON1 secretion is 
stimulated by HDL, which is also an important factor in 
the stabilization of the enzyme activity (James & Deakin, 
2004). PON1 received its name from paraoxon, the ac-
tive metabolite of the organophosphorus insecticide par-
athion, whose hydrolysis it catalyzes. PON1 also hydro-
lyses nerve agents (e.g., sarin, soman, VX) and arylesters, 
and metabolizes a number of drugs and pro-drugs via its 
lactonase activity (Costa et al., 2005). One natural physi-
ological function of PON1 appears to be the metabolism 
of toxic oxidized lipids of both low-density lipoproteins 
(LDL) and HDL particles (Mackness et al., 1996). The 
results of many studies have shown that PON1 prevents 
the formation of oxidized LDL, causes the inactivation 
of LDL-derived oxidized phospholipids once they are 
formed, and protects phospholipids in HDL from oxi-
dation. Due to these reasons, it is possible that PON1 
has a significant role in the prevention of cardiovascu-
lar diseases and atherosclerosis (McElveen et al., 1986; 
Mackness et al., 2006). Two closely related proteins, 
paraoxonase 2 (PON2) and paraoxonase 3 (PON3), 
have been identified as well. PON2 is expressed in many 
tissues, whereas PON3 is also contained in HDL par-
ticles. PON2 and PON3 have antioxidant properties, 
but they have no paraoxon-hydrolyzing activity (Aviram 
& Rosenblat, 2005). The most important difference be-
tween HDL and LDL lies in the fact that although LDL 
is the major target for the antioxidant action of PON1, 
LDL is not associated with PON1, and it is not able to 
stimulate PON1 secretion. Although the experiments of 
James et al. (1998) have shown no evidence for the as-
sociation of PON1 with LDL or very low-density lipo-
proteins (VLDL), the results of Deakin et al. (2005) have 
shown that TGs transport vector, VLDL, can modulate 
PON1 metabolism and activity in vitro, and that this li-
poprotein provides an alternative vector to HDL for 
promoting and sustaining an active, circulating form of 
PON1. They have also found that serum TGs are posi-
tively associated with the whole serum PON1 mass but 
negatively associated with its specific activity (Deakin et 
al., 2005). 
It is well known that PON1 activity can be modulated 
by diet (Costa et al., 2005; Soran et al., 2009). So, mice of 
the B6 strain fed an atherogenic diet for three months 
showed an approximately 60 % decrease in serum PON1 
activity and a similar reduction in liver PON1 mRNA 
levels. Feeding of both normal New Zealand white rab-
bits and rabbits transgenic for human apo AI with an 
atherogenic diet for 14 weeks resulted in a 50 % decrease 
in serum PON1 activity as well. Kudchodkar et al. (2000) 
proved that serum PON1 activity was significantly high-
er in rats fed triolein, lower in those fed fish oil, and 
unchanged in those fed tripalmitin compared with a con-
trol diet. On the other hand, high vegetable intake in 
humans led to a significantly lower PON1 activity (Kl-
eemola et al., 2002). 
e-mail: vbradam@mef.hr
Abbreviations: apo AI, apolipoprotein AI; apo E,  apolipoprotein 
E; CD, control diet; GEM, gemfibrozil; HSD, high sucrose diet; HDL, 
high-density lipoproteins; LDL, low-density lipoproteins; PON1, pa-
raoxonase 1; TGs, triacylglycerides; VLDL, very low-density lipopro-
teins
Vol. 57, No 3/2010
321–326
on-line at: www.actabp.pl
322           2010M. Macan and others
The influence of diet rich in sucrose on PON1 ac-
tivity is not known. As it is known that diet rich in 
sucrose increases the synthesis and secretion of VLDL 
by the liver and induces hypertriglyceridemia in humans 
and rats (Kannan et al., 1981; Strobl et al., 1989; Saku 
et al., 1996), our first object was to investigate the in-
fluence of HSD on PON1 activity in the plasma of 
normolipidemic rats and to determine the relationship 
between serum PON1 activity, TGs, HDL and total 
cholesterol. GEM, a derivative of fibric acid, is an ef-
fective cholesterol- and TGs-lowering agent which has 
been shown beneficial in the treatment of atherosclero-
sis. Since the data on the influence of GEM on PON1 
activity in animals and humans (Balogh et al., 2001; 
Beltowski et al., 2002) are controversial, the purpose of 
this study was to investigate the influence of chronic 
GEM treatment on plasma PON1 activity and lipids 
level in normolipidemic rats, and in rats with hypertrig-
lyceridemia caused by HSD.
MATERIAL AND METHODS
Test substances. Gemfibrozil (CAS–25812-30-0) was 
obtained from the Pharmaceutical and Chemical Com-
pany Lek, Ltd. (Ljubljana, Slovenia), and administered 
daily into the stomach by oral gavage (50 mg/kg body 
mass per day) in saline. HSD was commercially prepared 
by ICN (Milan, Italy). This diet contained 68  % (w/w) 
sucrose, 18 % casein, 8 % cottonseed oil, 2 % brewer’s 
yeast, 4 % salts mix USP II, vitamins and trace elements.
Treatment of animals. Adult male Wistar rats 
(180–220 g body mass) were fed either normal rat 
chow CD or HSD. The duration of all experiments 
was three or five weeks, and all experiments were 
conducted under identical conditions. The rats were 
randomised in two control groups (n = 7 each) and 
four experimental groups (n = 7 each). The two con-
trol groups were given CD for three and five weeks, 
and two experimental groups were given HSD for 
three and five weeks. The third and fourth experimen-
tal groups were fed CD and HSD for five weeks, to-
gether with GEM treatment in the last two weeks (the 
4th and 5th week of study). Following an overnight 
fast, the rats were killed at 9:00–10:00 h under diethyl 
ether anaesthesia, and blood plasma was obtained di-
rectly from the heart. Plasma samples for measuring 
PON1 activity were frozen immediately after sampling 
at –20 °C until further processing. Plasma lipids were 
measured 2–4 h after sampling. Handling and treat-
ment of the animals were conducted on basis of the 
international guidelines regarding the use of laboratory 
animals. The experiments had been approved by the 
local ethics committee.
PON1 activity. PON1 activity in the plasma was 
measured using synthetic diethyl-p-nitrophenyl phosphate 
(paraoxon, o,o-diethyl-p-nitrophenylphosphate, Sigma 
Chemical Co., London, UK) and CaCl2 (1 mM in 0.1 M 
Tris buffer, pH 7.4) as moderator. The activity toward 
paraoxon was determined by measuring the initial rate of 
substrate hydrolysis to p-nitrophenol. In brief, reaction 
(final volume 1100 μl) for the hydrolysis of paraoxon 
contained 200 μl of 0.1 M Tris buffer (pH 7.4), CaCl2 
and 800 μl of 1 mM paraoxon solution to which 100 
µl undiluted plasma was added to start the reaction. In-
crease in absorbance at 405 nm was monitored for 3–5 
min. The blank sample containing incubation mixture 
without plasma was run in parallel to correct for sponta-
neous substrate breakdown. The enzyme activity was cal-
culated from ε405 of p-nitrophenol (16 000 l ∙ mol–1 ∙ cm–1) 
and was expressed in μmol ∙ min–1 ∙ ml–1 (Beltowski et al., 
2004). 
Lipids and lipoproteins. Lipids were determined 
on an Olympus automatic analyser AU 2700 using 
original reagents produced by Olympus Diagnostics 
GmbH (Irish Branch, Lismeehan, Ireland). The plas-
ma concentrations of total cholesterol and TGs were 
determined by enzymatic colorimetric methods (Allain 
et al., 1974; Shepard & Whiting, 1990). HDL level was 
estimated using a compound method of immuno-in-
hibition with β-lipoprotein antibody in the first step, 
and enzymatic colorimetric measuring of accessible 
cholesterol in the second step (Bachorik, 1991). LDL 
was calculated mathematically from the concentrations 
of total cholesterol, TGs and HDL using Friedwald’s 
formula LDL = total cholesterol – TGs/2.2 – HDL (Re-
isen, 1998). The approximate formula applies only for 
plasma without chylomicrons and TGs concentration 
of less than 4.7 mmol/l. All lipid concentrations were 
expressed as mmol/l.
Glucose determination. Plasma concentration of glu-
cose was determined by enzymatic UV test with specific 
enzyme hexokinase. The test was performed on an auto-
matic Olympus analyser AU 2700 using original reagents 
produced by Olympus Diagnostics (Czok & Barthelmai, 
1962). 
Statistical analysis. Data are shown as the mean 
± standard deviation (S.D.). Descriptive statistics, 95 % 
confidence intervals and hypothesis testing were made 
using Statistics® for Windows Version 5.0. The statistical 
significance was determined by multivariate t-test (Hotel-
ling’s T test). All applied procedures were 2-tailed. The 
differences discussed in this paper were considered sig-
nificant at the P ≤0.05 level of significance. 
RESULTS
Our results for plasma lipids and glucose in rats treat-
ed with HSD, GEM, and their combination had been 
reported earlier (Bradamante et al., 2005), but in a dif-
ferent context in which we studied whether hypertrig-
lyceridemia increased plasma butyrylcholinesterase activ-
ity and whether GEM treatment decreased it. Since we 
took enough plasma samples for determing the activity 
of paraoxonase 1 as well, there was no need for new 
determinations and further animal sacrifice. We used the 
plasma results of lipids and glucose for the investigation 
of the relation between PON1 and plasma lipids. 
Effects of HSD on plasma PON1 activity and lipids 
There was a significant increase of PON1 activity fol-
lowing both three and five weeks of HSD supplementa-
tion compared with rats fed CD (Table 1). In the two 
treatments the significant increase of enzyme activity was 
32 % and 23 % compared with their control values (Ta-
ble 1). The values of total cholesterol, HDL and LDL 
did not significantly change after three or five weeks of 
HSD treatment (Table 1). However, compared with rats 
fed CD, the TGs level in rats on HSD was higher by 
20 % after three weeks of treatment, and significantly 
higher by 47 % after five weeks of treatment. The plas-
ma glucose level in the rats on HSD was significantly 
higher only after five weeks of treatment (Table 1) in 
comparison with the control. 
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Effects of GEM on plasma PON1 activity and lipids in 
the rats on CD and HSD 
In the normolipidemic rats on CD or in rats fed with 
HSD, the addition of GEM in the 4th and 5th weeks of 
the study caused a significant decrease of PON1 activ-
ity by 44 % and 33 % in comparison with rats on CD and 
HSD, but without GEM treatment (Table 2). The addition 
of GEM to the group of normolipidemic rats on CD in 
the 4th and 5th weeks of study caused a significant increase 
(P < 0.05) of total cholesterol and HDL by 33 % and 44 %, 
and a significant decrease of TGs level by 38 % (P < 0.05), 
while the value of LDL was unchanged in comparison with 
the control (Table 2). In rats fed HSD, the administration 
of GEM caused a significant increase of total cholesterol, 
HDL and LDL by 36 %, 44 % and 20 % (P < 0.05), while 
TGs level was unchanged vs. the control (Table 2). 
DISCUSSION
HSD causes an increase of serum TGs level and dys-
lipidemia as a consequence of sucrose hydrolysis into its 
constituents — glucose and fructose, and their conver-
sion into TGs (Diniz et al., 2006; Bar-On & Stein, 1994; 
Kannan et al., 1981). In this process, a few facts are im-
portant: (1) the conversion rate of fructose into lipids in 
the liver and the TGs secretion rate is greater than that 
of glucose (Kannan et al., 1981; Bar-On & Stein, 1994), 
(2) fructose administration does not stimulate the lipo-
protein lipase release, and (3) the inflow of fatty acids 
into the liver from adipose tissue is not depressed (Kan-
nan et al., 1981; Bar-On & Stein, 1994). Due to these 
reasons, our results obtained in rats that showed a sig-
nificant increase of plasma TGs levels by 47 % (P < 0.05, 
Table 1. Paraxonase activity, lipids and glucose in plasma of HSD rats
Mean ±S.E.D. are shown. 
Parameter CD*3 weeks
HSD*
3 weeks
P value
3 weeks
CD*
5 weeks
HSD*
5 weeks
P value
5 weeks
Paraoxonase
μmol/min per ml ( %)
0.172 ± 0.024
(100)
0.23 ± 0.05
(132)
(105–160)
0.026 0.236 ± 0.025
(100)
0.290 ± 0.048
(123)
(101–145)
0.045
Triglycerides**
mmol/l ( %)
0.76 ± 0.12
(100)
0.91 ± 0.31
(120)
(84–155)
0.248 0.81± 0.23
(100)
1.19 ± 0.33
(147)
(106–187)
0.027
Total cholesterol**
mmol/l ( %)
1.55 ± 0.27
(100)
1.44 ± 0.23
(93)
(74–112)
0.425 1.42 ± 0.21
(100)
1.52± 0.2
(107)
(90–123)
0.408
HDL **
mmol/l ( %)
0.84± 0.15
(100)
0.88 ± 0.15
(105)
(85–125)
0.581 0.84± 0.11
(100)
0.91± 0.13
(108)
(91–126)
0.298
LDL **
mmol/l ( %)
0.55± 0.13
(100)
0.44± 0.09
(80)
(56–103)
0.087 0.39± 0.08
(100)
0.40± 0.05
(102)
(83–122)
0.748
Glucose**
mmol/l ( %)
3.97 ± 0.59
(100)
11.11± 2.59
(280)
(225–335)
> 0.001 5.14± 1.5
(100)
10.02± 3.0
(195)
(141–249)
0.002
P values are results of comparison of HSD vs. CD with multivariate t–test. Relative changes ( %) and ranges (95 % CI) are given in brackets. *CD, 
control diet; HSD, high sucrose diet; **Results for plasma lipids and glucose were taken from Bradamante et al. (2005).
Table 2. Effect of GEM on paraxonase activity, lipids and glucose in plasma of rat
Rats were fed CD or HSD for 5 weeks. GEM was added in the 4th and 5th week. Mean ±S.E.D. are shown. 
Parameter CD* CD* + GEM*** P value HSD* HSD* + GEM*** P value
Paraoxonase
μmol/min per ml ( %)
0.236 ± 0.025
(100)
0.131 ± 0.022
(56)
(42–69)
0.001 0.290  ± 0.048
(100)
0.196 ± 0.019
(67)
(52–83)
0.001
Triglycerides**
mmol/l ( %)
0.81 ± 0.23
(100)
0.50 ± 0.12
(62)
(33–90)
0.013 1.19 ± 0.33
(100)
1.17 ± 0.43
(98)
(59–136)
0.899
Total cholesterol**
mmol/l ( %)
1.42 ± 0.21
(100)
1.89 ± 0.34
(133)
(109–156)
0.012 1.52 ± 0.2
(100)
2.11 ± 0.33
(136)
(120–153)
0.001
HDL**
mmol/l ( %)
0.84 ± 0.11
(100)
1.21 ± 0.27
(144)
(115–173)
0.007 0.91 ± 0.13
(100)
1.30 ± 0.25
(144)
(124–162)
0.001
LDL**
mmol/l ( %)
0.39 ± 0.08
(100)
0.37 ± 0.07
(95)
(72–118)
0.659 0.40 ± 0.05
(100)
0.48 ± 0.06
(120)
(105–135)
0.016
Glucose**
mmol/l ( %)
5.14  ± 1.5
(100)
6.65  ± 2.15
(129)
(86–173)
0.166 10.02 ± 3.0
(100)
8.64 ± 2.27
(86)
(51–122)
0.405
P values are results of comparison of CD + GEM vs. CD and HSD + GEM vs. HSD with multivariate t–test. Relative changes ( %) and ranges (95 % CI) 
are given in brackets. *CD, control diet; HSD, high sucrose diet; **Results for plasma lipids and glucose were taken from Bradamante et al. (2005); 
***GEM, gemfibrozil.
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Table 1) after five weeks of HSD treatment, could be 
predicted. The effect of HSD on TGs level was corre-
lated positively with the treatment duration (Table 1).
Various in vivo studies in animals and humans have 
provided evidence that HSD induces hyperlipidemia 
and oxidative stress (Diniz et al., 2006; Busserolles et al., 
2002a; 2002b) and that these conditions per se negatively 
modulate the PON1 activity (Durrington et al., 2001). 
It has also been found that HSD decreases the activity 
of superoxide dismutase (Beltowski et al., 2000) and in-
creases plasma concentration of thiobarbituric acid-reac-
tive substances (Beltowski et al., 2000; Busserolles et al., 
2002a). Considering that consumption of HSD negative-
ly modulates the PON1 activity, we expected a decrease 
of its activity. Our results have shown however, that 
in comparison with control groups, HSD treatment for 
three or five weeks causes hypertriglyceridemia (signifi-
cant after five weeks) and a significant increase of PON1 
activity by 32 % and 23 % (Table 1), while the level of 
HDL is unchanged. This positive association between 
HSD, hypertriglyceridemia and higher PON1 activities 
obtained in our results can be partially explained by the 
results of Deakin et al. (2005) who examined the influ-
ence of VLDL on PON1 secretion. In those in vitro ex-
periments, they showed that VLDL promoted the secre-
tion of PON1 from a transfected Chinese hamster ovary 
model and from transfected hepatocytes in a high-affin-
ity, saturable manner. They also showed that low levels 
of active PON1 were associated with VLDL in the hu-
man serum, and that the VLDL-associated PON1 activ-
ity was proportional to plasma TGs concentrations. Al-
though Deakin et al. (2005) found that serum TGs were 
positively associated with the whole serum PON1 mass 
but negatively with the specific enzyme activity, we sup-
pose that the positive association between serum TGs 
concentrations, PON1 activity and HDL, noticeable in 
our results, was a direct consequence of the experimental 
conditions in vivo. Based on the results of Beltowski et al. 
(2000), Busserolles et al. (2002a) and Deakin et al. (2005), 
we think that the positive influence of HSD on plasma 
PON1 activity found in our experiments is a result of 
higher level of TGs caused by HSD, that overcame the 
possible oxidant effect of HSD on the enzyme activity. 
Our results are backed up by the results of experiments 
in rats fed different diet, that differently influenced the 
activity of antioxidant enzymes. High-calorie high-fat and 
high-calorie normal-fat diet decreased the activity of su-
peroxide dismutase but increased that of glutathione per-
oxidase in rats (Beltowski et al., 2000). We also suggest 
that higher PON1 activity can insure further protection 
of both HDL and VLDL from oxidation. 
The addition of GEM to the group of normolipidem-
ic rats on CD in the 4th and 5th weeks of study caused 
a significant decrease of TGs level (Table 2). This result 
was expected from the mechanism of action of GEM 
and other fibrates on metabolism of TGs, and is con-
firmed in numerous studies in animals (Dashti & Ontko, 
1983; Petit et al., 1988; Ozansoy et al., 2001) and humans 
(Yoshida et al., 1998; Balogh et al., 2001; Chen et al., 
2001). On the other hand, the addition of GEM to the 
group of rats on HSD did not cause any change in TGs 
level (Table 2). We suggest that the stimulatory effect 
of HSD on TGs synthesis in the liver is much stronger 
than the known inhibitory action of GEM on the plas-
ma TGs level. The addition of GEM to the group of 
normolipidemic rats on CD, or to the group of rats on 
HSD caused in the both groups a significant increase of 
total cholesterol and HDL vs. their control groups (Ta-
ble 2). Although the positive influence of GEM on to-
tal cholesterol and HDL obtained in our results could 
be predicted and is congruent with the results of other 
authors (Krause & Newton, 1986; Krause et al., 1996), 
it is important to mention that the data about the influ-
ence of GEM and other fibrates on lipoprotein metabo-
lism are not unequivocal. Thus, the total, free cholesterol 
and HDL were decreased in male rats after treatment 
with clofibrate for seven days in doses of 0.5 mmol/kg 
(Dashti & Ontko, 1983), while HDL in cholesterol-fed 
rats was increased by GEM 3.6-fold, by fenofibrate 1.3-
fold and by ciprofibrate 1.2-fold, but not by clofibrate, 
when dosed per os at 50 mg/kg for two weeks (Krause 
& Newton, 1986; Krause et al., 1996). GEM was also a 
significant and major determinant of elevated apolipo-
protein E (apo E) and apo AI, while bezafibrate pro-
duced opposite effects, a decrease of HDL, apo E and 
liver TGs, and tended to increase LDL as well (Krause 
& Newton, 1986; Krause et al., 1996). Since apo AI and 
apo E are the major HDL peptides in the rat, it was 
concluded that GEM, which produces a rise in the se-
rum concentrations of both apo AI and apo E, and 
enhances the hepatic synthesis and secretion of apo E, 
produces the greatest elevations of HDL as well (Krause 
& Newton, 1986). We also suggest that the increase of 
HDL, obtained in our results, is a consequence of the 
increased synthesis of apo E in the liver. The mechanism 
that is responsible for the effects of GEM on lipopro-
tein metabolism is not known in details, but recent stud-
ies have shown that many of the above effects of GEM 
and other fibrates are mediated by their interaction with 
peroxisome proliferator-activated receptor α (PPARα) 
(Steals et al., 1992). Although rodents are more suscep-
tible to peroxisome proliferators than are dogs, rhesus 
monkeys or humans, there is no evidence yet that GEM 
and fibrates are exogenous ligands for PPAR receptors. 
The present study has shown that GEM treatment 
causes opposite effects on HDL level and PON1 activ-
ity. After GEM treatment, plasma HDL was significantly 
higher and PON1 activity significantly lower in the rats 
on CD and HSD (Table 2) in comparison with the val-
ues from rats on CD or on HSD diet but without GEM 
treatment (Table 2). Plasma PON1 is located on HDL, 
and drugs, such as GEM and other fibrates, which in-
crease HDL, might therefore increase the enzyme activ-
ity as well. This relationship was shown by Balogh et al. 
(2001), who demonstrated that twice-daily administration 
of 600 mg of GEM for three months in type-2 diabetic 
patients caused an increase of serum PON1 activity and 
HDL level. Similar results, i.e. increased PON1 activity 
and HDL level were obtained in patients with coronary 
heart disease, who were treated with micronised fenofi-
brate for three months (Paragh et al., 2003). In another 
case, bezafibrate (400 mg daily) and GEM (600 mg twice 
daily) administered in patients with type IIb hyperlipo-
proteinemia for eight weeks significantly reduced the se-
rum TGs concentration and increased HDL without an 
effect on the PON1 activity (Durrington et al., 1998). It 
was concluded that although both the PON1 concen-
tration and its activity are correlated with the level of 
serum HDL and apo AI, the strength of these correla-
tions is not high and it is therefore likely that in their 
physiological concentration ranges the levels of PON1 
and other HDL components can fluctuate independently 
(Durrington et al., 1998). In contrast to the above results, 
Beltowski et al. (2002) found that in normolipidemic rats 
fenofibrate treatment decreased plasma level of lipid per-
oxidation products without changing the total plasma 
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antioxidant capacity, TGs or cholesterol concentrations, 
but it caused a significant dose-dependent decrease of 
plasma PON1 activity by 20 % to 40 %. It was sug-
gested that this effect of fenofibrate on PON1 activity 
would be potentially its adverse effect, which could be 
masked by beneficial changes in the plasma lipid profile 
(Beltowski et al., 2002). Our results have confirmed this 
presumption.
It is known that GEM has both antioxidant and pro-
oxidant actions and that it influences the oxidant status. 
First, it was proved that GEM together with its metabo-
lite M1 may show antioxidant properties in vitro (Yoshida 
et al., 1998; Aviram et al., 1998; Kawamura et al., 2000) 
and in vivo (Ozansoy et al., 2001; Chen et al., 2001) on 
LDL, VLDL, and HDL oxidation, which could be re-
lated to their free radical scavenging activity, as well as 
to their metal ion chelation capacities. Second, the op-
posite evidence can be found in some other data. Thus, 
Scatena et al. (1997) have shown that a single oral ther-
apeutic dose of GEM, acting as a primer, in human 
volunteers significantly enhances the induced reactive-
oxygen-species production by overall blood phagocytes, 
polymorphonuclear leukocytes and monocytes, when 
these cells are stimulated by phorbol myristate acetate. 
Consequently, the enhancing effect of GEM on the re-
active oxygen metabolism of leukocytes represents a 
possibility of damage at the level of different cells and 
tissues. GEM also showed its oxidative effects on ani-
on influx and metabolism in normal and β-thalassemic 
erythrocytes (Tellone et al., 2008). Taking into considera-
tion the results of Scatena et al. (1997) and Tellone et al. 
(2008) mentioned above, and the negative influence of 
fenofibrate and GEM on PON1 activity that was seen 
in the results of Beltowski et al. (2002), and in the our 
results as well, we think that the significant decrease of 
PON1 activity in our results is primarily a consequence 
of the oxidant action of GEM. At the molecular level, it 
is known that GEM, like other fibrates, induces marked 
proliferation of PPARα in rats (Arnaiz et al., 1995), and 
peroxisomal β oxidation of fatty acids, which is the main 
source of PPARα-mediated reactive hydrogen peroxide 
(H2O2) production. Because PPARα in rodents is ex-
pressed primarily in the liver, and to a lesser extent in 
kidney, heart and skeletal muscles, it is possible that the 
oxidative stress induced by GEM damages the hepato-
cytes and hampers the synthesis of PON1. Our results 
regarding the concentrations of malonyldialdehyde and 
PON1 activity in the plasma and other tissues of rats 
treated with GEM have supported this hypothesis about 
its strong prooxidant activity (unpublished). On the 
other hand, examination of human liver biopsy material, 
obtained from patients receiving GEM or other fibrates, 
has demonstrated marginal or no increase in peroxisomal 
volume, densities or number (Lock et al., 1989). Due to 
these reasons, it is very likely that the different effect of 
GEM on PON1 activity in humans and in rats is a con-
sequence of the evident species differences in the sensi-
tivity to fibrates. 
In the present study GEM treatment has caused a 
small but significant increase of LDL in rats fed HSD 
(Table 2). A similar medical report was described in 
hypertriglyceridemic patients, who were frequently found 
to have incomplete VLDL to LDL conversion before 
treatment (Kissebah et al., 1981). Because the plasma 
cholesterol in rats is essentially represented by HDL, we 
suggest that this increase of LDL in rats is without any 
importance. In contrast, in patients with hypertriglyceri-
demia, the increase of LDL caused by GEM has shown 
a possible atherogenic effect of GEM treatment. 
In conclusion, the results of our study have clear-
ly demonstrated that HSD increases the plasma TGs 
level and the activity of PON1 in rats without chang-
ing the total cholesterol, HDL and LDL. Because HSD 
did not per se negatively modulate the PON1 activity, 
we think that the significant increase of PON1 activity 
was mainly due to the direct influence of higher level 
of TGs caused by HSD, which promoted higher secre-
tion of PON1 from hepatocytes. In rats on CD and 
HSD, GEM caused a significant decrease of PON1 ac-
tivity and a significant increase of total cholesterol and 
HDL vs. the controls, while TGs level was significantly 
decreased only in the rats on normal diet. Because GEM 
in the liver of rats stimulates strongly the proliferation of 
peroxisomes, β oxidation, and production of H2O2, it is 
possible that the oxidative stress induced by GEM is a 
cause of damage of hepatocytes and leads to decreased 
synthesis of PON1. 
In view of these results further studies of the influ-
ence of different types of diet and GEM on the oxidant 
status and antioxidant enzymes are clearly needed. 
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